SCHEMBL3608488

SCHEMBL3608488

COC(=O)c1cccnc1NC(=O)c1ccc(Cl)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
KMT2A Q03164 5/20 0.55
RAB9A P51151 5/20 0.55
NPC1 O15118 4/20 0.55
MEN1 O00255 3/20 0.51
KDM4E B2RXH2 2/20 0.51
TSHR P16473 1/20 0.51
ALDH1A1 P00352 7/20 0.50
HPGD P15428 5/20 0.50
CNR2 P34972 1/20 0.49
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TP53 P04637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617679 0.86 RAB9A (0.59) KMT2ARAB9ANPC1MEN1KDM4E
SCHEMBL3622350 0.81 KMT2A (0.58) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL3622343 0.79 TSHR (0.63) POLBKMT2AMEN1KDM4ETSHR
SCHEMBL3618963 0.78 POLB (0.55) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL3614428 0.78 KMT2A (0.61) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL18640732 0.76 HTT (0.76) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL12426304 0.75 CNR2 (0.60) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL3615049 0.75 KMT2A (0.57) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL14344414 0.75 MEN1 (0.59) POLBKMT2ARAB9ANPC1MEN1
SCHEMBL3604192 0.75 KMT2A (0.57) POLBKMT2ARAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
EP-1928868-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF Bayer HealthCare AG (DE) 2008-06-11 EP disclosed
WO-2007028520-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use PPOX, XDH, PNPO POLB 1225/4885KMT2A 4031/4885RAB9A 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.